Drug Profile
Imidafenacin - Kyorin Pharmaceutical/Ono Pharmaceutical
Alternative Names: KRP 197; KRP-197OD; ONO 8025; ONO-8025OD; Staybla; Staybla OD Tablets; Uritos; Uritos OD TabletsLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyorin Pharmaceutical
- Developer Ajanta Pharma; Chong Kun Dang; Eisai Co Ltd; Kyorin Pharmaceutical; Ono Pharmaceutical
- Class Imidazoles; Small molecules; Urologics
- Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Overactive bladder; Pollakisuria; Urinary incontinence
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 12 Apr 2021 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Japan (PO)
- 01 Aug 2018 Imidafenacin licensed to Faes Farma in Latin America
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Overactive bladder(Adjunctive treatment, Combination therapy) in Japan (PO, Fast dissolve)